Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d'Etudes et de Recherche sur …

…, P Delaval, J Cadranel, P Bonniaud, G Prévot… - Autoimmunity …, 2017 - Elsevier
Objective To guide nosology and classification of patients with eosinophilic granulomatosis
with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods …

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

…, L Savale, X Jaïs, V Cottin, G Prevot… - European …, 2017 - Eur Respiratory Soc
Current European guidelines recommend periodic risk assessment for patients with
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …

Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome

V Cottin, J Le Pavec, G Prévot, H Mal… - European respiratory …, 2010 - Eur Respiratory Soc
This study aims to describe the haemodynamic and survival characteristics of patients with
pulmonary hypertension in the recently individualised syndrome of combined pulmonary …

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

…, MT Leccia, M Jaffro, S Collot, G Prévot… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …

Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open …

…, P Magro, L Savale, G Prévot… - The Lancet …, 2022 - thelancet.com
Background Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for
inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised …

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double …

…, N Zhang, Y Mi, X Zhu, P Jansa, G Prévot… - The Lancet …, 2017 - thelancet.com
Background Macitentan is beneficial for long-term treatment of pulmonary arterial
hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) …

[HTML][HTML] External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry

…, P De Groote, V Cottin, G Prévot… - European …, 2022 - Eur Respiratory Soc
Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial
hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk …

Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension

…, F Picard, J Pichon, P Poubeau, G Prévot… - American journal of …, 2021 - atsjournals.org
Rationale: The relationship between the initial treatment strategy and survival in pulmonary
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival …

Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis

…, J Cadranel, B Wallaert, A Tazi, B Maître, G Prévot… - Thorax, 2018 - thorax.bmj.com
Introduction Idiopathic pulmonary fibrosis (IPF) has an unpredictable course corresponding
to various profiles: stability, physiological disease progression and rapid decline. A minority …

Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis

…, V Cottin, S Marchand-Adam, G Prevot… - European …, 2016 - Eur Respiratory Soc
Telomerase reverse transcriptase (TERT) or telomerase RNA (TERC) gene mutation is a
major monogenic cause of pulmonary fibrosis. Sequencing of TERT/TERC genes is proposed …